Metagenomi, Inc. is a precision genetic medicine company. The Company is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). It has also developed a modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. The Company uses artificial intelligence and its metagenomics platform to develop curative genetic medicines.
äŒæ¥ã³ãŒãMGX
äŒç€ŸåMetagenomi Inc
äžå Žæ¥Feb 09, 2024
æé«çµå¶è²¬ä»»è
ãCEOãIrish (Jian)
åŸæ¥å¡æ°202
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Feb 09
æ¬ç€Ÿæåšå°5959 Horton St
éœåžEMERYVILLE
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·94608
é»è©±çªå·15108714880
ãŠã§ããµã€ãhttps://metagenomi.co/
äŒæ¥ã³ãŒãMGX
äžå Žæ¥Feb 09, 2024
æé«çµå¶è²¬ä»»è
ãCEOãIrish (Jian)